ZA200308555B - Powder formulation disintegrating system and method for dry powder inhalers. - Google Patents
Powder formulation disintegrating system and method for dry powder inhalers. Download PDFInfo
- Publication number
- ZA200308555B ZA200308555B ZA200308555A ZA200308555A ZA200308555B ZA 200308555 B ZA200308555 B ZA 200308555B ZA 200308555 A ZA200308555 A ZA 200308555A ZA 200308555 A ZA200308555 A ZA 200308555A ZA 200308555 B ZA200308555 B ZA 200308555B
- Authority
- ZA
- South Africa
- Prior art keywords
- chamber
- particles
- air
- carrier
- inhaler
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims description 169
- 239000000203 mixture Substances 0.000 title claims description 116
- 238000009472 formulation Methods 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 19
- 239000002245 particle Substances 0.000 claims description 293
- 239000003814 drug Substances 0.000 claims description 127
- 229940079593 drug Drugs 0.000 claims description 121
- 239000010419 fine particle Substances 0.000 claims description 70
- 239000008188 pellet Substances 0.000 claims description 69
- 239000000853 adhesive Substances 0.000 claims description 50
- 230000001070 adhesive effect Effects 0.000 claims description 50
- 239000013078 crystal Substances 0.000 claims description 47
- 230000003434 inspiratory effect Effects 0.000 claims description 40
- 230000008021 deposition Effects 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 27
- 238000009826 distribution Methods 0.000 claims description 18
- 230000002829 reductive effect Effects 0.000 claims description 17
- 230000009471 action Effects 0.000 claims description 16
- 239000000443 aerosol Substances 0.000 claims description 13
- 230000003993 interaction Effects 0.000 claims description 13
- 230000036961 partial effect Effects 0.000 claims description 13
- 230000033001 locomotion Effects 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 230000000717 retained effect Effects 0.000 claims description 12
- 238000013459 approach Methods 0.000 claims description 11
- 230000008901 benefit Effects 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 11
- 230000001133 acceleration Effects 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 8
- 230000004888 barrier function Effects 0.000 claims description 7
- 229940112141 dry powder inhaler Drugs 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 230000002411 adverse Effects 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 4
- 206010007134 Candida infections Diseases 0.000 claims description 4
- 201000003984 candidiasis Diseases 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 206010013952 Dysphonia Diseases 0.000 claims description 3
- 208000010473 Hoarseness Diseases 0.000 claims description 3
- 238000005411 Van der Waals force Methods 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 239000002085 irritant Substances 0.000 claims description 3
- 231100000021 irritant Toxicity 0.000 claims description 3
- 206010008469 Chest discomfort Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000013583 drug formulation Substances 0.000 claims description 2
- 239000003570 air Substances 0.000 description 206
- 238000005054 agglomeration Methods 0.000 description 102
- 238000013461 design Methods 0.000 description 25
- 238000002156 mixing Methods 0.000 description 22
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 21
- 229960001375 lactose Drugs 0.000 description 21
- 239000008101 lactose Substances 0.000 description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 20
- 239000002775 capsule Substances 0.000 description 20
- 210000002345 respiratory system Anatomy 0.000 description 16
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 15
- 239000012876 carrier material Substances 0.000 description 15
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 11
- 229960004436 budesonide Drugs 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000035508 accumulation Effects 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 241001417527 Pempheridae Species 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000011164 primary particle Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 108010078777 Colistin Proteins 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 4
- 230000021715 photosynthesis, light harvesting Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000012387 aerosolization Methods 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000011362 coarse particle Substances 0.000 description 3
- 229960001127 colistin sulfate Drugs 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003746 surface roughness Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000032953 Device battery issue Diseases 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 229940053670 asmanex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001595 flow curve Methods 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 229940107791 foradil Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011044 inertial separation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940090585 serevent Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229930195727 α-lactose Natural products 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10129703A DE10129703A1 (de) | 2001-06-22 | 2001-06-22 | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200308555B true ZA200308555B (en) | 2004-02-17 |
Family
ID=7688810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200308555A ZA200308555B (en) | 2001-06-22 | 2003-11-03 | Powder formulation disintegrating system and method for dry powder inhalers. |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1397174B1 (hr) |
JP (1) | JP4116537B2 (hr) |
KR (1) | KR100904955B1 (hr) |
CN (1) | CN100337699C (hr) |
AR (1) | AR034616A1 (hr) |
AT (1) | ATE477826T1 (hr) |
AU (1) | AU2009200071B2 (hr) |
BG (1) | BG66589B1 (hr) |
BR (2) | BR0210026A (hr) |
CA (1) | CA2445892C (hr) |
CY (1) | CY1110924T1 (hr) |
CZ (1) | CZ302528B6 (hr) |
DE (2) | DE10129703A1 (hr) |
DK (1) | DK1397174T3 (hr) |
ES (1) | ES2350973T3 (hr) |
HK (1) | HK1064313A1 (hr) |
HR (1) | HRP20040058B1 (hr) |
HU (1) | HU227457B1 (hr) |
IL (3) | IL158614A0 (hr) |
MX (1) | MXPA03011550A (hr) |
NO (1) | NO332992B1 (hr) |
NZ (1) | NZ530308A (hr) |
PL (1) | PL204900B1 (hr) |
PT (1) | PT1397174E (hr) |
RU (1) | RU2291717C2 (hr) |
SI (1) | SI1397174T1 (hr) |
SK (1) | SK288034B6 (hr) |
TW (1) | TW567075B (hr) |
UA (1) | UA74648C2 (hr) |
WO (1) | WO2003000325A1 (hr) |
ZA (1) | ZA200308555B (hr) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
EP1488819A1 (en) | 2003-06-16 | 2004-12-22 | Rijksuniversiteit te Groningen | Dry powder inhaler and method for pulmonary inhalation of dry powder |
RU2258539C1 (ru) * | 2004-03-23 | 2005-08-20 | Чучалин Александр Григорьевич | Порошковый ингалятор |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
DE102005046645B3 (de) * | 2005-09-29 | 2006-07-20 | Braunform Gmbh | Pulverinhalator |
DE102005046644B3 (de) * | 2005-09-29 | 2006-07-20 | Braunform Gmbh | Pulverinhalator |
DE102006007495A1 (de) * | 2006-02-17 | 2007-08-23 | Siegfried Generics International Ag | Dispergiereinheit |
EP2004258A1 (en) * | 2006-04-13 | 2008-12-24 | Boehringer Ingelheim Microparts Gmbh | Dispensing device |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2569359T3 (es) * | 2007-07-06 | 2016-05-10 | Vectura Delivery Devices Limited | Inhalador |
EP2020249A1 (de) | 2007-08-01 | 2009-02-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Inhalator |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
DE102007041720A1 (de) * | 2007-09-04 | 2009-03-05 | Alfred Von Schuckmann | Vorrichtung zur Darreichung eines blisterverpackten Medikaments |
US8439033B2 (en) * | 2007-10-09 | 2013-05-14 | Microdose Therapeutx, Inc. | Inhalation device |
WO2009079078A1 (en) | 2007-12-14 | 2009-06-25 | Labogroup S.A.S. | Delivering aerosolizable food products |
ES2546025T3 (es) * | 2008-01-24 | 2015-09-17 | Vectura Delivery Devices Limited | Inhalador |
EP2082764A1 (en) * | 2008-01-24 | 2009-07-29 | Boehringer Ingelheim International GmbH | Inhaler |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
UA99656C2 (en) * | 2008-05-23 | 2012-09-10 | Оцука Фармасьютикал Ко., Лтд. | Powder inhaler |
EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
EP2177521A1 (en) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
EP2210615A1 (en) | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
EP2221055A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
EP2221297A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
CA2791847C (en) * | 2009-03-04 | 2017-05-02 | Mannkind Corporation | An improved dry powder drug delivery system |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
GB0919465D0 (en) * | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
EP2498846A4 (en) * | 2009-11-13 | 2014-08-27 | Merck Sharp & Dohme | DRUG PRODUCTS, DRY POWDER INHALATORS AND POLYFLUX COLLISION DEVICE ARRANGEMENTS |
EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
EP2455081A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
EP2455080A1 (en) | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
US8974450B2 (en) | 2011-02-03 | 2015-03-10 | Covidien Lp | System and method for ablation procedure monitoring using electrodes |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
EP2747815B1 (en) | 2011-09-07 | 2017-11-29 | Concentrx Pharmaceuticals, Inc. | Dry powder inhalation device |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2617448A1 (en) | 2012-01-20 | 2013-07-24 | Almirall S.A. | Inhalation device for powdered drugs |
EP2617449A1 (en) | 2012-01-20 | 2013-07-24 | Almirall S.A. | Inhalation device for powdered drugs |
EP2617450A1 (en) | 2012-01-20 | 2013-07-24 | Almirall S.A. | Inhaltion device for powdered drugs |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
EP2668941A1 (en) | 2012-05-31 | 2013-12-04 | Almirall, S.A. | Novel dosage form and formulation of abediterol |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
WO2014095663A1 (en) | 2012-12-17 | 2014-06-26 | Almirall, S.A. | New use of aclidinium |
MA38260B1 (fr) | 2012-12-18 | 2018-04-30 | Almirall Sa | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 |
UY35332A (es) | 2013-02-15 | 2014-11-28 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
WO2015091287A1 (en) | 2013-12-19 | 2015-06-25 | Almirall S.A. | Dosage formulation comprising salmeterol and fluticasone propionate |
EP2944343A1 (en) | 2014-05-15 | 2015-11-18 | AstraZeneca AB | Dry powder inhaler |
PT3151893T (pt) * | 2014-06-06 | 2018-05-18 | Univ Groningen | Um inalador de pó seco acionado por respiração |
ES2701202T3 (es) * | 2014-11-26 | 2019-02-21 | Vectura Delivery Devices Ltd | Dispositivo de apertura de envases tipo blíster para inhalador de polvo seco |
JP2018501903A (ja) | 2015-01-14 | 2018-01-25 | レスピラ セラピューティクス インコーポレイテッドRespira Therapeutics,Inc. | パウダー分散方法および装置 |
MA41938A (fr) | 2015-04-21 | 2018-02-28 | Almirall Sa | Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques |
WO2016202800A1 (en) | 2015-06-16 | 2016-12-22 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
WO2017076990A1 (en) | 2015-11-05 | 2017-05-11 | Almirall, S.A. | Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide |
RU2634258C1 (ru) * | 2016-11-08 | 2017-10-24 | федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) | Наполнитель для капсульного ингалятора |
AU2017369978A1 (en) * | 2016-11-30 | 2019-04-11 | Philip Morris Products S.A. | Inhaler with sized cavity |
CN110494181B (zh) | 2017-03-28 | 2022-03-18 | 康森特里克斯药物公司 | 用于输送干粉药物的装置和方法 |
CN107123354B (zh) * | 2017-05-21 | 2019-03-19 | 谭淞文 | 分选花形微粒载体的吸入器、呼吸道及肺部模型设备集成 |
TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Nrf2路徑的新穎化合物 |
CN111526747B (zh) * | 2018-02-19 | 2023-11-07 | 菲利普莫里斯生产公司 | 干粉吸入器 |
CN110201278B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
CN110201279B (zh) * | 2018-02-28 | 2021-05-11 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
CN110201280B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药装置的吸嘴和吸入给药装置 |
CN111514418B (zh) * | 2019-06-12 | 2022-01-14 | 中南大学湘雅二医院 | 一种自吸式经鼻粉末材料给送装置 |
CN111359060A (zh) * | 2020-02-20 | 2020-07-03 | 深圳麦克韦尔科技有限公司 | 雾化吸嘴及雾化装置 |
CN113750331B (zh) * | 2021-08-18 | 2022-08-16 | 华中科技大学 | 一种干粉吸入器 |
CN114632235B (zh) * | 2022-03-04 | 2023-04-25 | 华中科技大学 | 一种干粉吸入器 |
CN115006656A (zh) * | 2022-05-18 | 2022-09-06 | 苏州易合医药有限公司 | 一种可连续提供肺部活性剂粉雾剂的给药装置 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1478138A (en) * | 1973-07-18 | 1977-06-29 | Beecham Group Ltd | Device for the administration of powders |
IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
DE4211475A1 (de) * | 1991-12-14 | 1993-06-17 | Asta Medica Ag | Pulverinhalator |
DE4239402A1 (de) * | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
ATE177323T1 (de) | 1992-12-18 | 1999-03-15 | Schering Corp | Inhalator für pulverförmige medikamente |
ES2152427T3 (es) * | 1994-10-04 | 2001-02-01 | Procter & Gamble | Pulverizacion electrostatica de material particulado. |
DE19522416C2 (de) * | 1995-06-21 | 2003-11-20 | Sofotec Gmbh & Co Kg | Vorrichtung zum Dispergieren von Pulver in einem Luftstrom zur Verwendung mit Pulver-Inhalatoren |
NZ502870A (en) * | 1995-06-21 | 2001-06-29 | Asta Medica Ag | Inhaler for powdered medicaments comprising a visual display device to indicate the discharge status of the inhaler |
FR2738153B1 (fr) * | 1995-09-04 | 1998-01-02 | Valois | Appareil d'inhalation destine a distribuer des doses precises et reproductibles de produit pulverulent |
EP1129705A1 (en) * | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
-
2001
- 2001-06-22 DE DE10129703A patent/DE10129703A1/de not_active Withdrawn
-
2002
- 2002-06-12 TW TW091112804A patent/TW567075B/zh not_active IP Right Cessation
- 2002-06-15 BR BR0210026-6A patent/BR0210026A/pt active IP Right Grant
- 2002-06-15 IL IL15861402A patent/IL158614A0/xx unknown
- 2002-06-15 DE DE60237366T patent/DE60237366D1/de not_active Expired - Lifetime
- 2002-06-15 HU HU0400212A patent/HU227457B1/hu unknown
- 2002-06-15 UA UA20031211618A patent/UA74648C2/uk unknown
- 2002-06-15 MX MXPA03011550A patent/MXPA03011550A/es active IP Right Grant
- 2002-06-15 CN CNB02812121XA patent/CN100337699C/zh not_active Expired - Lifetime
- 2002-06-15 AT AT02780833T patent/ATE477826T1/de active
- 2002-06-15 BR BRPI0210026A patent/BRPI0210026B8/pt not_active IP Right Cessation
- 2002-06-15 CA CA2445892A patent/CA2445892C/en not_active Expired - Lifetime
- 2002-06-15 PL PL365946A patent/PL204900B1/pl unknown
- 2002-06-15 JP JP2003506966A patent/JP4116537B2/ja not_active Expired - Lifetime
- 2002-06-15 RU RU2004102037/14A patent/RU2291717C2/ru active
- 2002-06-15 CZ CZ20040046A patent/CZ302528B6/cs not_active IP Right Cessation
- 2002-06-15 WO PCT/EP2002/006610 patent/WO2003000325A1/en active Application Filing
- 2002-06-15 SK SK27-2004A patent/SK288034B6/sk unknown
- 2002-06-15 KR KR1020037016628A patent/KR100904955B1/ko active IP Right Grant
- 2002-06-15 NZ NZ530308A patent/NZ530308A/en not_active IP Right Cessation
- 2002-06-15 EP EP02780833A patent/EP1397174B1/en not_active Expired - Lifetime
- 2002-06-15 ES ES02780833T patent/ES2350973T3/es not_active Expired - Lifetime
- 2002-06-15 DK DK02780833.6T patent/DK1397174T3/da active
- 2002-06-15 PT PT02780833T patent/PT1397174E/pt unknown
- 2002-06-15 SI SI200230925T patent/SI1397174T1/sl unknown
- 2002-06-21 AR ARP020102359A patent/AR034616A1/es active IP Right Grant
-
2003
- 2003-10-27 IL IL158614A patent/IL158614A/en active IP Right Grant
- 2003-11-03 ZA ZA200308555A patent/ZA200308555B/en unknown
- 2003-12-17 NO NO20035654A patent/NO332992B1/no not_active IP Right Cessation
-
2004
- 2004-01-06 BG BG108512A patent/BG66589B1/bg unknown
- 2004-01-20 HR HRP20040058AA patent/HRP20040058B1/hr not_active IP Right Cessation
- 2004-09-17 HK HK04107144.6A patent/HK1064313A1/xx not_active IP Right Cessation
-
2009
- 2009-01-08 AU AU2009200071A patent/AU2009200071B2/en not_active Expired
-
2010
- 2010-11-17 CY CY20101101039T patent/CY1110924T1/el unknown
-
2011
- 2011-02-01 IL IL210983A patent/IL210983A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2445892C (en) | Powder formulation disintegrating system and method for dry powder inhalers | |
US6681768B2 (en) | Powder formulation disintegrating system and method for dry powder inhalers | |
US7344734B2 (en) | Powder formulation | |
AU2018204860B2 (en) | Inhalable medicaments | |
JP2001517984A (ja) | 吸入装置 | |
CA3206868A1 (en) | Powder dispersion methods and devices | |
JP2016073675A (ja) | 薬物製品、乾燥粉末吸入器、および、ポリフラックスコライダ配置体 | |
AU2002350483A1 (en) | Powder formulation disintegrating system and method for dry powder | |
Donovan | Influence of carrier particle size and surface roughness on the aerosol performance of DPI formulations |